Rybelsus (2019): The first and only oral GLP-1 receptor agonist approved for Type 2 Diabetes
As evidence for GLP-1 cardiovascular benefits strengthens, policy discussions about broader coverage continue across Canadian provinces
Ookhtens, M., Hobdy, K., Corvasce, M., Aw, T
This also supports the finding that the cardiovascular benefits are not restricted to those agents structurally similar to human GLP-1 but are more likely a class effect that is seen in all GLP-1RAs
200 units of 100 mcg each
Compared with free curcumin, curcumin encapsulated in NPs demonstrates enhanced anti-proliferative effects [159], offering a promising strategy for breast cancer treatment